Clinical Trials Directory

Trials / Completed

CompletedNCT03501134

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

ACTION: A Longitudinal Observational Study of Quality of Life, Functional Capacity and Physical Function in Glioblastoma Patients Treated With Tumor-Treating Fields

Status
Completed
Phase
Study type
Observational
Enrollment
20 (actual)
Sponsor
Duke University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

This purpose of this study is to describe the effect of Tumor Treating Fields (NovoTTF) on quality of life (QOL), including exercise, sleep quality, and mood, in patients with World Health Organization (WHO) Grade IV malignant glioma who have been prescribed and approved to receive Optune™. This is an observational, longitudinal study, meaning that information about QOL will be collected over time while the patient is using the NovoTTF device (for example, Optune™).

Detailed description

Patients will be provided with a Fitbit Charge HR™, which they will begin wearing immediately to collect baseline information. The study team will teach the patients how to use the Fitbit and the associated smart phone application. Patients will also set an account with a platform that will provide information from the Fitbit (number of steps, sleep behaviors, and exercise log) to the study team. Patients will also have blood drawn, do a 6-minute walk test, and complete questionnaires at clinic visits 1, 8, 16, and 24 weeks after receiving the Fitbit. At the end of the study, patients will return the Fitbit to the study team.

Conditions

Interventions

TypeNameDescription
DEVICENovoTTFWe are studying the effect of Tumor Treating Fields (NovoTTF), for example Optune™, on the quality of life, including exercise, sleep quality, and mood, of patients with malignant glioma who plan to use the NovoTTF device.

Timeline

Start date
2018-08-08
Primary completion
2021-06-03
Completion
2021-06-03
First posted
2018-04-18
Last updated
2021-06-09

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03501134. Inclusion in this directory is not an endorsement.